Yahoo Web Search

Search results

1. • 

     Merck acquires EyeBio in up to $3B deal By Proactive Investors

     Investing.com· 2 days ago

     Merck & Co Inc (NYSE:MRK, ETR:6MK) announced it is acquiring Eyebio, a privately held...

2. • Merck & Co. sees clear vision to new ophthalmology assets with $3B EyeBio buy

     FierceBiotech· 3 days ago

     Merck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech. Merck will take on a pipeline of vision ...

3. • 

     Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports

     WSAU Wausau· 3 days ago

     (Reuters) -Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company...

4. • 

     Merck (MRK) to Buy Private Ophthalmology Company EyeBio

     Zacks via Yahoo Finance· 2 days ago

     Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a...

5. • Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald

     Roanoke-Chowan News-Herald· 3 days ago

     Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK)of its portfolio company EyeBio for a potential value of $3 billion This acquisition reflects ...

6. • 

     Merck to buy eye drug developer for $1.3B

     BioPharma Dive via Yahoo Finance· 3 days ago

     An acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.

7. • Merck Announces Third-Quarter 2024 Dividend

     Morningstar· 3 days ago

     Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.77 per share of the company’s common ...

8. • 

     Hedge Funds Are Loading Up On This Dividend Stock

     Benzinga via Yahoo Finance· 5 days ago

     The markets are adjusting to the high interest rates environment, with all the major US stock indices reporting strong gains in May 2024. However, even...

9. • Merck On Track for Largest Percent Decrease Since October 2023 — Data Talk

     Morningstar· 4 days ago

     Merck & Co., Inc. (MRK) is currently at $126.30, down $3.19 or 2.46% --Would be lowest close since April 19, 2024, when it closed at $125.78 --On pace for ...

10. • 

      Roche’s Sabry retires; Duchenne drug fails confirmatory test

      BioPharma Dive via Yahoo Finance· 4 days ago

      The veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative...